Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-CC5 · 1 trial · 1 indication
Adverse events were reported for single-ascending doses (SAD) or multiple ascending doses (MAD) of ALN-CC5 when administered to healthy adult subjects and of multiple doses (MD) in patients with paroxysmal nocturnal hemoglobinuria (PNH)
| Arm | Type | Description |
|---|---|---|
| ALN-CC5 | ACTIVE_COMPARATOR | - |
| Sterile Normal Saline (0.9% NaCl) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-CC5 | DRUG | Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection |
| Sterile Normal Saline (0.9% NaCl) | DRUG | calculated volume to match active comparator |
Inclusion Criteria: * Adequate complete blood counts, liver and renal function * 12-lead electrocardiogram (ECG) within normal limits * Female subjects of child bearing potential agreeing to use a protocol specified method of contraception * Male subjects agreeing to use protocol specified methods ...
ALN-CC5 is an investigational drug being studied for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare blood disorder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ALN-CC5 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ALNY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria.
ALN-CC5 is in Phase 1 clinical development. A Phase 1/2 study has been completed, involving healthy volunteers and patients with Paroxysmal Nocturnal Hemoglobinuria. The drug remains investigational and is not yet approved for any use.
ALN-CC5 has been studied in a completed Phase 1/2 trial with the identifier NCT02352493. This randomized, double-blind, placebo-controlled study enrolled 62 participants, including healthy volunteers and patients with Paroxysmal Nocturnal Hemoglobinuria, at sites in Spain and the United Kingdom.
ALN-CC5 is the investigational name for this drug candidate. No alternative names have been disclosed in the clinical trial information. It is being studied specifically for Paroxysmal Nocturnal Hemoglobinuria and is not known to be marketed under any other name.